SAN DIEGO (AP) _ Fate Therapeutics Inc. (FATE) on Wednesday reported a loss of $76.1 million in its second quarter.

The San Diego-based company said it had a loss of 79 cents per share.

The results topped Wall Street expectations. The average estimate of 12 analysts surveyed by Zacks Investment Research was for a loss of 86 cents per share.

The clinical-stage biotech company that develops stem cell treatments posted revenue of $18.5 million in the period, also exceeding Street forecasts. Ten analysts surveyed by Zacks expected $13.4 million.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on FATE at https://www.zacks.com/ap/FATE

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News